The bladder cancer targeting drug erdafitinib of Johnson&Johnson was approved in the EU
因醉鞭名马幌
发表于 2024-8-24 14:04:25
189
0
0
On August 23rd, Janssen Cilag International NV, a subsidiary of Johnson&Johnson, announced that the European Commission (EC) has approved BALVERSA& reg; (erdafitinib) is a daily oral monotherapy used to treat adult patients with unresectable or metastatic urothelial carcinoma (mUC).
CandyLake.com 系信息发布平台，仅提供信息存储空间服务。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
声明：该文观点仅代表作者本人，本文不代表CandyLake.com立场，且不构成建议，请谨慎对待。
转播
猜你喜欢
- 欧州委員会、アップルの相互運用義務を明確にするプログラムを開始
- Google wins EU advertising antitrust case, court withdraws 1.49 billion euros fine
- グーグルがEU広告独占禁止事件で勝訴、裁判所が14億9000万ユーロの罰金刑を破棄
- Sanofi's targeted therapy drug for chronic obstructive pulmonary disease, Dabitou, has been approved in China
- The targeted therapy drug for chronic obstructive pulmonary disease, Dabitou, has been approved in China
- Xiaopeng Motors denies privately negotiating with the EU: spreading rumors in an organized and rhythmic manner
- 小鵬自動車、EUとの私的交渉を否定：組織的にデマを流し、リズムを持っている
- Trump claims to have received a call from Cook seeking help regarding Apple being fined heavily by the European Union
- トランプ氏、クック氏からの「助けを求める」電話にアップルがEUから巨額の罰金を科されたと主張
- ノフノイド：スミグロルペプチド2.4 mgは肝線維化症状の顕著な改善を示し、2025年上半期に米国とEUに規制承認を提出する
